

REMARKS

Upon entry of the present amendment, claims 32-54 have been canceled, claims 55-77 have been added, and claims 55-77 are pending.

Paragraph 2: Applicant notes that the references have been placed into the file, Applicant considers the references to be cumulative to those already of record.

Paragraph 3: A corrected substitute Abstract is enclosed.

Paragraph 4: Old claim (now 70) has been amended to recite specific tumor types. Support for this amendment is in the specification at page 157. Old claims 37-46 (now 60-69) are directed to pharmaceutical compositions and not to specific cancers.

Paragraph 5: Old claim 32 (now 55) has been amended to recite in its preamble "A pyridylalkane, pyridylalkene or pyridylalkine acid amide compound of formula (I)".

h) Dependent claims have been amended to make the preamble consistent.

e) Old claim 35 (now 58) has been amended to be consistent with the claims from which it depends.

w) Old claim 50 (now 73) has been amended to delete "nucleofuge" and replace it with "leaving group" as defined at page 55 of the specification.

Paragraph 6: Old claim 32 (now 55), old claim 37 (now 60) and old claim 49 (now 72) have been amended to disclaim the compounds described in Ishihara et al.

Paragraph 7:

Support for pyridyl -A -C(0)- and NR¹¹ - C(0)-4-(CR⁹10¹⁰)m-R⁸ is at page 22 of the specification.

Paragraph 8:

- a) Spelling has been corrected.
- b) Spelling has been corrected.
- c) Rewritten as "R⁷" has the same meaning as R⁶".
- d) Changed "meanings" to "meaning".
- e) Added indication to point of attachment.
- f) Point of attachment and groups have been defined.
- g) Deleted "either".
- h) Added indicated of point of attachment.
- i) Changed "meanings" to "meaning".
- j) "In ring systems" has been deleted.
- k) Spelling has been corrected.
- l) Corrected Markush.
- m) Corrected spelling.
- n) Corrected Markush.
- o) Deleted definitions.
- p) Deleted definitions.
- q) Corrected Markush.
- r) Deleted definitions.
- s) Deleted definitions.
- t) Deleted definitions.
- u) Corrected spelling.
- v) Corrected Markush.
- w) Corrected spelling.
- x) Corrected Markush.
- y) Deleted definitions.
- z) Deleted defintions.
- aa) Deleted defintions.
- ab) Deleted definitions.
- ac) Deleted definitions.

- ad) Deleted definitions.
- ae) Corrected Markush.
- af) Deleted definitions.
- ag) Deleted definitions.
- ah) Deleted definitions.
- ai) Deleted definitions.
- aj) Deleted definitions.
- ak) Deleted definitions.
- al) Corrected spelling.
- am) Deleted definitions.
- an) Deleted definitions.
- ao) Deleted definitions.
- ap) Deleted definitions.
- aq) Deleted definitions.
- ar) Deleted definitions.
- as) Deleted definitions.
- at) Deleted definitions.
- au) Changed "the method" to "the composition".
- av) Support for the dosage amounts is claimed at page 130 of the specification.
- aw) Deleted second occurrence of 2.
- ax) Added definitions.
- ay) The second X was change to X^1 .
- az) Changed " $=CR^8R^9$ " to " $=CR^9R^{10}$ ".
- ba) Added definitions of variables.
- bb) Deleted Ar^1 and Ar^2 .
- bc) Deleted R^{11} , R^{12} , Ar^1 and Ar^2 .
- bd) Change " R_{12} " to R^{12} ".
- be) Added definitions of variables.
- bf) Added definition.
- bg) Added definition.
- bh) Changed " $=CR^8R^9$ " to " $+CR^9R^{10}$ ".
- bi) Added indication of point of attachment.

The Commissioner is hereby authorized to charge any additional fees which may be required in this application to Deposit Account No. 06-1135.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By 

James P. Krueger
Registration No. 35,234

Date: **MAY 19 2003**

FITCH, EVEN, TABIN & FLANNERY
120 S. LaSalle St., Suite 1600
Chicago, Illinois 60603
Telephone: 312/577-7000
Fax: 312/577-7007